Medicaid Policy and Liver Transplant for Alcohol-Associated Liver Disease

被引:15
|
作者
Lee, Brian P. [1 ]
Vittinghoff, Eric [2 ]
Pletcher, Mark J. [2 ]
Dodge, Jennifer L. [2 ]
Terrault, Norah A. [3 ]
机构
[1] Univ Calif San Francisco, Dept Gastroenterol, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA
[3] Univ Southern Calif, Div Gastrointestinal & Liver Dis, 1450 San Pablo Ave,HC4 Room 3054, Los Angeles, CA 90033 USA
关键词
D O I
10.1002/hep.31027
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aims In some states, liver transplantation (LT) for alcohol-associated liver disease (ALD) is covered by Medicaid only with documentation of abstinence and/or alcohol rehabilitation. Different Medicaid policies may affect the distribution of LT for ALD, particularly post-2011, as centers have adopted early (i.e., specific abstinence period not required) LT practices. Approach and Results We surveyed Medicaid policies in all states actively performing LT and linked state policies to prospectively collected national registry data on LT recipients from 2002 to 2017 with ALD as the primary listing diagnosis. We categorized Medicaid policies for states as "restrictive" (requiring documentation of a specific abstinence period and/or rehabilitation) versus "unrestrictive" (deferring to center eligibility policies). Difference-of-differences analysis, comparing 2002-2011 versus 2012-2017, evaluated whether restrictive policies were associated with decreased proportion of LTs paid by Medicaid among patients with ALD post-2011. We performed sensitivity analyses to account for any differences by diagnosis of hepatocellular carcinoma, hepatitis C virus, nonalcoholic steatohepatitis, or Medicare insurance. We also performed a sensitivity analysis to account for any difference by prevalence of ALD among restrictive versus unrestrictive states. Of 10,836 LT recipients in 2002-2017, 7,091 were from 24 states in the restrictive group and 3,745 from 14 states in the unrestrictive group. The adjusted proportion (95% confidence interval) of LTs paid by Medicaid among restrictive versus unrestrictive states between 2002 and 2011 was 17.6% (15.4%-19.8%) versus 18.9% (15.4%-22.3%) (P = 0.54) and between 2012 and 2017, 17.2% (14.7%-19.7%) versus 23.2% (19.8%-26.6%) (P = 0.005). In difference-of-differences analysis, restrictive (versus unrestrictive) policies were associated with a 4.7% (0.8%-8.6%) (P = 0.02) absolute lower adjusted proportion of LTs for ALD paid by Medicaid post-2011. Conclusions Restrictive Medicaid policies are present in most states with active LT centers and are associated with lower proportions of LTs for ALD paid by Medicaid post-2011 compared to states with unrestrictive Medicaid policies. Reevaluation of Medicaid alcohol use policies may be warranted, to align more closely with contemporary center-level practices.
引用
收藏
页码:130 / 139
页数:10
相关论文
共 50 条
  • [41] Revisiting the '6-month' liver transplant rule for alcohol-associated liver disease: It is time for a change but not without a sound policy first
    Sirpal, Sanjeev
    Yoshida, Eric M.
    Chandok, Natasha
    CANADIAN LIVER JOURNAL, 2018, 1 (04): : 153 - 155
  • [42] Patient reflections, challenges, and supports related to early liver transplant for severe alcohol-associated liver disease
    Chen, Po-Hung
    Sung, Hannah C.
    Punchhi, Gopika
    Krach, Michelle
    Greenberg, Ross
    Gianaris, Kevin
    Teles, Mayan
    Kaplow, Katya
    Wheatley, Jason
    Cameron, Andrew M.
    Chander, Geetanjali
    LIVER TRANSPLANTATION, 2023, 29 (07) : 745 - 756
  • [43] Disparities in the Decision to Evaluate for Liver Transplant in Patients Referred With Underlying Alcohol-Associated Liver Disease (ALD)
    Ornelas, Rafael
    Hamilton, Julia
    Clark, Ellen
    Naugler, Scott
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1229 - S1230
  • [44] Early Liver Transplant for Alcohol-associated Liver Disease Has Excellent Survival but Higher Rates of Harmful Alcohol Use
    Musto, Jessica A.
    Palmer, Geralyn
    Nemer, Mary
    Schell, Trevor
    Waclawik, Gabrielle
    Glover, Quarshie
    Lucey, Michael R.
    Osman, Fay
    Rice, John P.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (08) : 1646 - 1656
  • [45] POST-TRANSPLANT OUTCOMES IN ALCOHOL-ASSOCIATED LIVER DISEASE AND UNTREATED ALCOHOL USE DISORDER
    Azhari, Hassan
    Havlichek, Daniel, III
    Watt, Kymberly
    Taner, Timucin
    Sanchez, William
    Schneekloth, Terry D.
    Simonetto, Douglas A.
    HEPATOLOGY, 2021, 74 : 862A - 863A
  • [46] Alcohol-Associated Liver Disease: Managing the Dual Pathology of Liver Disease and of Alcohol Use Disorder
    Arab, Juan Pablo
    Louvet, Alexandre
    Thiele, Maja
    Winder, Gerald S.
    Wong, Robert J.
    Singal, Ashwani K.
    GASTROENTEROLOGY, 2025, 168 (02)
  • [47] Indications for and outcomes of liver transplantation in patients with alcohol-associated liver disease
    Phillips, Paulina K.
    Caldis, Matthew W.
    Hristov, Alexander D.
    Lee, Alexander S.
    Lucey, Michael R. .
    MINERVA GASTROENTEROLOGICA E DIETOLOGICA, 2018, 64 (02) : 126 - 137
  • [48] Recidivism for Non-Alcoholic Fatty Liver Disease and Alcohol-Associated Liver Disease in Liver Transplant: Is All Recidivism Treated Equally?
    Robinson, Benjamin L.
    Ciobanu, Camelia
    Russell, Gregory B.
    Russo, Mark W.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S1124 - S1124
  • [49] Modeling alcohol-associated liver disease in a human Liver-Chip
    Nawroth, Janna C.
    Petropolis, Debora B.
    Manatakis, Dimitris, V
    Maulana, Tengku Ibrahim
    Burchett, Gabriel
    Schlunder, Katharina
    Witt, Anke
    Shukla, Abhishek
    Kodella, Konstantia
    Ronxhi, Janey
    Kulkarni, Gauri
    Hamilton, Geraldine
    Seki, Ekihiro
    Lu, Shelly
    Karalis, Katia C.
    CELL REPORTS, 2021, 36 (03):